Aurinia Pharmaceuticals Inc.
AUPH
$15.35
$0.171.12%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.76% | 20.62% | 20.38% | 20.62% | 25.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.76% | 20.62% | 20.38% | 20.62% | 25.59% |
| Cost of Revenue | 29.13% | 25.07% | 27.72% | 34.99% | 1.11% |
| Gross Profit | 16.77% | 19.14% | 17.82% | 16.59% | 36.13% |
| SG&A Expenses | -19.71% | -28.47% | -40.83% | -40.79% | -33.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -200.80% | -142.74% | -110.95% | 379.99% | 1,299.07% |
| Total Operating Expenses | -23.32% | -19.94% | -25.07% | -22.85% | -22.49% |
| Operating Income | 154.25% | 216.24% | 828.68% | 526.03% | 234.13% |
| Income Before Tax | 156.64% | 219.88% | 1,432.72% | 495.41% | 229.91% |
| Income Tax Expenses | -8,415.36% | -8,483.28% | -10,303.13% | -25.22% | -17.90% |
| Earnings from Continuing Operations | 418.03% | 648.43% | 4,893.08% | 445.14% | 220.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 418.03% | 648.43% | 4,893.08% | 445.14% | 220.43% |
| EBIT | 154.25% | 216.24% | 828.68% | 526.03% | 234.13% |
| EBITDA | 117.75% | 148.23% | 324.57% | 20,213.33% | 404.20% |
| EPS Basic | 444.44% | 696.05% | 5,205.15% | 466.82% | 224.51% |
| Normalized Basic EPS | 113.65% | 138.41% | 303.21% | 920.33% | 302.44% |
| EPS Diluted | 431.87% | 686.77% | 5,021.98% | 455.08% | 222.15% |
| Normalized Diluted EPS | 111.80% | 136.54% | 301.69% | 879.39% | 297.16% |
| Average Basic Shares Outstanding | -5.87% | -6.43% | -6.12% | -4.45% | -2.46% |
| Average Diluted Shares Outstanding | -5.00% | -5.39% | -4.57% | -2.13% | 0.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |